Ovulation Inducing Drugs Market Report 2026

The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.7 billion in 2025 to $5 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of infertility disorders, increasing awareness of reproductive health, growing incidence of pcos, improved access to fertility clinics, expansion of assisted reproductive technologies.

The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to delayed childbearing trends, increasing female workforce participation, rising demand for minimally invasive fertility treatments, growing healthcare expenditure on women health, expanding access to fertility treatments in emerging economies. Major trends in the forecast period include rising use of first-line oral ovulation inducers, growing preference for personalized fertility protocols, increasing adoption of combination drug therapies, expanding use of ovulation drugs in pcos management, shift toward early infertility diagnosis and treatment.

The increasing prevalence of women’s infertility is expected to drive the growth of the ovulation-inducing drug market in the coming years. Women’s infertility is a biological condition in which a woman is unable to conceive or carry a pregnancy to term despite engaging in regular, unprotected sexual intercourse for about a year or longer. This condition is often linked to ovulatory dysfunction, hormonal imbalances, and other reproductive health complications that hinder natural conception. Ovulation-inducing drugs help address these issues by stimulating the hormonal pathways that regulate ovulation and promoting the release of mature eggs to support pregnancy. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 17.5% of the global adult population - about 1 in 6 individuals - experience infertility during their lifetime. Therefore, the rising prevalence of women’s infertility is driving the growth of the ovulation-inducing drug market.

Major companies operating in the ovulation-inducing drugs market are pursuing strategic partnerships to develop innovative and more accessible fertility treatments. Strategic partnerships drive market growth by enabling companies to combine expertise, share resources, reduce development costs, and accelerate the launch of advanced and more affordable fertility therapies for patients worldwide. For instance, in October 2023, Cosette Pharmaceuticals Inc., a US-based pharmaceutical company, partnered with Mark Cuban Cost Plus Drug Company, a US-based online pharmacy, to make CLOMID® (clomiphene citrate) more affordable for patients. This collaboration leverages Cosette’s expertise in fertility medications and Cost Plus Drug Company’s transparent, low-cost pricing model to expand patient access. By reducing financial barriers, the partnership aims to improve treatment adherence and support more individuals seeking fertility care globally.

In February 2024, Novo Holdings, a Denmark-based life sciences investment company, acquired Catalent Inc. for $16.5 billion. Through this acquisition, Novo Holdings aims to enhance its drug development and manufacturing capabilities by leveraging Catalent’s expertise in advanced formulation, biologics production, gene therapies, and specialized drug delivery technologies. This strategic move is intended to accelerate innovation, streamline development processes, and expand Novo Holdings’ global presence in high-growth therapeutic areas. Catalent Inc. is a US-based pharmaceutical company that manufactures a range of drug products, including ovulation-inducing drugs.

Major companies operating in the ovulation inducing drugs market are Ferring Pharmaceuticals Inc., EMD Serono Inc., Merck And Co. Inc., Gedeon Richter plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc., LIVZON Pharmaceutical Group Inc.

North America was the largest region in the ovulation-inducing drugs market in 2025. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ovulation inducing drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the ovulation inducing drugs market by increasing costs associated with active pharmaceutical ingredients, hormones, and injectable formulations that rely on cross-border supply chains. These impacts are more pronounced in hormone-based and parenteral drug segments, with Asia-Pacific and parts of Europe being most affected due to their role in pharmaceutical manufacturing and exports. Higher tariffs have led to pricing pressure and margin constraints for manufacturers and fertility clinics. However, tariffs have also encouraged local production, contract manufacturing partnerships, and supply chain diversification, supporting long-term market resilience.

The ovulation inducing drugs market research report is one of a series of new reports that provides ovulation inducing drugs market statistics, including ovulation inducing drugs industry global market size, regional shares, competitors with a ovulation inducing drugs market share, detailed ovulation inducing drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ovulation inducing drugs industry. This ovulation inducing drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ovulation-inducing drugs are medications used to stimulate the ovaries and promote the release of mature eggs (ovulation) in women who have irregular menstrual cycles or face infertility issues. These drugs work by influencing the hormonal balance in the body, specifically targeting the hormones that regulate ovulation.

The main types of ovulation-inducing drugs include hormones and therapeutic drugs. Hormone drugs are medications designed to alter or mimic the effects of naturally occurring hormones in the body. They can be administered via oral, topical, and other routes and are used by a range of end users, including hospitals, homecare providers, specialty clinics, and others.

The ovulation-inducing drugs market consists of sales of clomiphene citrate (Clomid), letrozole (Femara), gonadotropins, human chorionic gonadotropin (hCG), bromocriptine (Cycloset, Parlodel). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.